Asian Spectator


The Times

.

Mangroves Documentary Premieres, Exploring How Cities and Wetlands Coexist

SHENZHEN, CHINA – Media OutReach Newswire – 17 November 2026 – Guangdong Radio and Television has unveiled Mangroves, a three-part ecological documentary filmed in 4K ultra-high de...

Offload and programmable adapters drive Ethernet adapter reven...

LONDON, Oct. 29, 2020 /PRNewswire-AsiaNet / -- The total ethernet adapter market hit $585 million in Q2 2020 according to Omdia's latest Ethernet Network Adapter Equipment Market Tracker.For...

kiOra Makes International Debut in Kuala Lumpur and Announces Release Date for Debut Single Coco Music Video

Music Video to Premiere Worldwide on 8 August, with Exclusive Advance Screening at HEAD IN THE CLOUDS Music & Arts Festival in Los AngelesKUALA LUMPUR, MALAYSIA – Media OutReach N...

ICONSIAM Showcases Thai Culture with ICONSIAM THAICONIC LOY KRATHONG Festival, Strengthening Thailand’s Global Standing

This year’s Loy Krathong event at ICONSIAM celebrates Thai cultural heritage, promotes sustainability, and shines a global spotlight on Thai cultureBANGKOK, THAILAND - Media OutReach ...

OpenFin Launches Workspace to Accelerate Industry Standardizat...

NEW YORK and LONDON, April 27, 2021 /PRNewswire-AsiaNet/ -- OpenFin, the operating system (OS) for enterprise productivity, today announced the launch of OpenFin Workspace, a revolutionary p...

A first for Taiwan, BIO Asia-Taiwan 2019 to be held in Taipei, 24 July, with BIO’s president Jim Greenwood to attend

As a sign of its international importance, the BIO Asia-Taiwan 2019 exhibition will feature 18 national pavilions, while the conference will feature speakers from 25 countries  TAIPEI...

Design Spectrum of Hong Kong Design Centre Presents ‘Re: Full Gamut’ Exhibition

Unveils How Cross-disciplinary Design Shapes the Vibrant Design Scene in the Guangdong-Hong Kong-Macao Greater Bay Area HONG KONG SAR - Media OutReach - 30 November 2023 - Design Spectrum, ...

Xinhua Silk Road: Chinese Rural Revitalizing 2019 and 1st Foru...

HANGZHOU, China, Dec. 3, 2019 /PRNewswire-AsiaNet/ -- Chinese Rural Revitalizing 2019 and the First Forum on Belt & Road Initiative Agricultural and Rural Development convened on Decembe...

Canonical Ubuntu Core 22 is now available - optimised for IoT ...

LONDON, June 17, 2022 /PRNewswire-AsiaNet/ -- The ultra-secure embedded Ubuntu introduces support for real-time compute in robotics and industrial applications.Canonical today announced that...

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

TOKYO, Mar 26, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL).

This application is based on data from a multicenter, open-label, single-arm Phase II clinical study (study 205) conducted in Japan for patients with relapsed or refractory CTCL or PTCL to evaluate the efficacy and safety of this agent.

This study achieved the primary endpoint and exceeded a predetermined threshold with statistical significance: the objective response rate (ORR) of CTCL and PTCL patients in total (n=36) was 36.1% (95% confidence interval (CI): 20.8-53.8). The ORRs of each subtype were 31.6% (95% CI:12.6-56.6) for CTCL (n=19) and 41.2% (95%CI: 18.4-67.1) for PTCL (n=17).

The five most frequent adverse events observed in this study were increased aspartate aminotransferase (AST) (89.2%), increased alanine aminotransferase (ALT) (86.5%), hypoalbuminaemia (70.3%), lymphopenia (70.3%), and pyrexia (51.4%).

Denileukin diftitox (genetic recombinant) is a fusion protein of the receptor-binding portion of interleukin-2 (IL-2) and diphtheria toxin that specifically binds to the IL-2 receptor on the surface of tumoral lymphocyte. The antitumor effect of denileukin diftitox depends on the intracellular delivery of diphtheria toxin which inhibits protein synthesis and induces cell death. The agent has been evaluated as a drug with high medical need by the "Study Group for Unapproved Drugs/Off-Label Drugs for High Medical Needs"(1), and Eisai has been requested to develop it by the Ministry of Health, Labour and Welfare.

Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals.

(1) The Study Group set up within the Ministry of Health, Labour and Welfare with the purpose of contributing to enhancing the development of drugs and indications that have not been approved in Japan (unapproved drugs/off-label drugs) by pharmaceutical companies. In addition to evaluating the medical needs of unapproved drugs/off-label drugs, their responsibilities include evaluating the applicability of the drug to an Application with Public Knowledge, and the adequacy of additional clinical studies that need to be conducted for filing applications for approval, and so on.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegaluk casinos not on gamstophttps://www.capitolcitycinema.org/grandpashabet girisStreamEastStreamEastjojobet